Global Cancer Monoclonal Antibodies Market - Growth, trend, and forecast (2015-2020)

News provided by

Mar 08, 2016, 04:28 ET

NEW YORK, March 8, 2016 /PRNewswire/ -- The Global Cancer Monoclonal Antibodies Market was valued at USD 27 billion for the year 2015, and is expected to grow at a CAGR of around 8-15% from 2015 to 2020. Cancer is a severe disease, which starts from a single cell; cancer genetically transforms a normal cell into a tumor cell. Gradually, it spreads to more cells. There is no one definite cause for cancer. The interaction between a person's genetic factor and other external agents (physical carcinogens, such as ultraviolet and ionizing radiation, chemical carcinogens, and biological carcinogens) can roughly be cited as the major cause. In 2012, WHO reported 14 million new cancer cases and 8.2 million deaths due to cancer. The most common types of cancer that caused death are lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer and esophageal cancer. There is a steady rise and incidence of cancer annually. Drugs haven't been able to provide complete cure for any cancer. Moreover, all these drugs available for cancer as chemotherapeutic agents have adverse side-effects because the drugs tend to affect the normal, healthy cells along with the cancerous cells. Hence, there is huge amount of research and development going on all over the world to combat this deadly disease.

Monoclonal antibodies are specifically cloned antibodies that have the capability to identify cancer cells, bind to proteins on their surface and simulate an immune response. Due to their specificity, they are expected and have been proved to lessen the adverse effects of cancer to a much higher level. Most major pharmaceutical companies are investing for research on monoclonal antibodies. The drug research companies have also collaborated with many academics and institutions like National Institutes of Health, USA, National Cancer Institute, USA and many others for research and development of cancer drugs/ monoclonal antibodies. Due to the highly customizable nature of monoclonal antibodies, various organizations, research institutes and companies are using it as a tool to target various cancers.

The global monoclonal antibody market has been segmented based on:

Therapeutic application
Breast,
Liver
Blood
Brain
Colorectal
Hodgkins and non-hodgkins lymphoma
leukemia
Others
Types of monoclonal antibodies
Murine antibodies
Chimeric and humanized antibodies
Fully humanized antibodies
Conjugated cancer therapies using monoclonal antibodies
Immunoliposome
Radioimmunotherapy
ADEPT
Immunocytokines.
Avastin, Rituxan, Bexxar, Kadcyla, Erbitux, Arzerra, Yervoy, Adcetris, Herceptin are some of the well-marketed monoclonal antibodies. A large patient population, severity of the disease, unavailability of good drugs and side effects of the existing drugs are the main reasons for the big void in the monoclonal antibodies market for new entrants to fill in. With only few monoclonal antibodies in the market exclusively for cancer therapies, there is always a good prospect for a new entrant. Conjugated therapies, using monoclonal antibodies, have been observed to give better results compared to stand alone treatment. Currently, there is a trend towards more research in conjugated therapies. With growing collaborations with institutes and companies, a very good market is expected in the near future. North America has the largest market for cancer monoclonal antibodies. India, China and Australia are expected to have a large market in the near future.

The key players in this market are Amgen, Bristol Meyer Squibb, GlaxoSmithKline, Roche, Eli Lilly, ImmunoGen, Novartis, Genmab and others.

Drivers

Large global patient pool
Severity of the disease
Unavailability of completely curing drugs
Side effects of the existing drugs
More specificity of monoclonal antibodies in targeting cancer cells

Challenges

Stringent regulatory guidelines
Long duration of research and development
Long duration of clinical trials
High cost for research and development
Read the full report: http://www.reportlinker.com/p03687627-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com